Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Fractyl Health, Inc. ( (GUTS) ) is now available.
On May 17, 2025, Fractyl Health, Inc. announced new preclinical data from its Rejuva smart GLP-1 gene therapy platform at the ASGCT 2025 Annual Meeting. The data highlighted RJVA-001’s potential to deliver durable, nutrient-responsive GLP-1 secretion from pancreatic beta cells, mimicking natural hormone regulation with low systemic GLP-1 levels. This suggests a significant advantage over current GLP-1 drugs, and the therapy demonstrated strong efficacy, targeted delivery, and a favorable safety profile. The company plans to submit the first Clinical Trial Application for RJVA-001 by June 2025, advancing towards first-in-human studies.
The most recent analyst rating on (GUTS) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s stock score is primarily weighed down by its precarious financial situation, characterized by high leverage and ongoing losses. While the company shows promise in its clinical advancements and market interest for its products, financial challenges and valuation concerns remain significant risks. Technical analysis indicates some upward momentum, but potential overbought conditions suggest caution. Overall, the stock score reflects a balance between future potential and current financial instability.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health is a metabolic therapeutics company focused on innovative approaches to treat the root causes of obesity and type 2 diabetes (T2D). The company aims to transform the treatment of metabolic diseases from chronic management to durable, disease-modifying therapies targeting organ-level root causes. Fractyl Health is based in Burlington, MA.
Average Trading Volume: 242,997
Technical Sentiment Signal: Buy
Current Market Cap: $82.77M
Find detailed analytics on GUTS stock on TipRanks’ Stock Analysis page.